We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drugmakers looking to replicate Dr. Reddy’s Laboratories’ strategy of marketing near-equivalent versions of brand drugs years before the basic patent expires will have to put their plans on hold after a recent appeals court ruling effectively ended Dr. Reddy’s challenge to Pfizer’s top-selling hypertension drug Norvasc, according to industry analysts.
Drug giant Pfizer has filed a patent infringement lawsuit against generic firm Teva Pharmaceuticals over its bid to market a version of Pfizer’s top-selling arthritis drug Celebrex (celecoxib).
Generic firms hoping to replicate Dr. Reddy’s Laboratories’ strategy of marketing near-equivalent versions of brand drugs years before the basic patent expires will have to put their plans on hold after a recent appeals court ruling effectively ended Dr. Reddy’s challenge to Pfizer’s top-selling hypertension drug Norvasc, according to industry analysts who have reviewed the ruling.
Drugmaker Atrix Laboratories has received a stay postponing a patent infringement fight over its prostate cancer drug Eligard (leuprolide acetate) injectable suspension, the firm said Friday.
The Pfizer-Dr. Reddy’s patent litigation involving Pfizer’s Norvasc antihypertensive treatment may be a signal to the brand industry that patent extensions cover a broader area, giving them more protection against generic competition, according to legal experts who have been analyzing the case for the past week.
In two new developments on the reimportation front last week, Pfizer denied two Canadian drug wholesalers Pfizer products, saying they violated the company’s unauthorized distribution policy, and a Chicago couple became the first plaintiffs in a federal class action lawsuit against the HHS and the FDA to allow the reimportation of drugs from Canada.
The generic drug industry can’t do much about a new legal-delay tactic brand companies are considering using against generic competition which employs the fear of crippling financial damages to prevent them from launching products, according to the head of the FTC.
A class action lawsuit alleging 20 drug manufacturers overstated their average wholesale prices (AWPs) and inflated Medicare and other third-party payments for prescription drugs by engaging in fraud, kickbacks and conspiracy can proceed, a federal district judge in Boston has ruled.
A federal district judge in Boston has refused to dismiss a class action lawsuit alleging that 20 drug manufacturers overstated their average wholesale prices (AWPs) and inflated Medicare and other third-party payments for prescription drugs by engaging in fraud, kickbacks and conspiracy.